United Therapeutics Co. (UTHR) Shares Sold by Schroder Investment Management Group

Schroder Investment Management Group trimmed its position in United Therapeutics Co. (NASDAQ:UTHR) by 32.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 224,624 shares of the biotechnology company’s stock after selling 107,675 shares during the period. Schroder Investment Management Group owned approximately 0.52% of United Therapeutics worth $28,725,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Trexquant Investment LP bought a new position in shares of United Therapeutics in the third quarter valued at approximately $510,000. DekaBank Deutsche Girozentrale grew its holdings in shares of United Therapeutics by 33.0% in the third quarter. DekaBank Deutsche Girozentrale now owns 75,228 shares of the biotechnology company’s stock valued at $9,410,000 after acquiring an additional 18,659 shares in the last quarter. Ontario Teachers Pension Plan Board grew its holdings in shares of United Therapeutics by 82.2% in the third quarter. Ontario Teachers Pension Plan Board now owns 21,500 shares of the biotechnology company’s stock valued at $2,749,000 after acquiring an additional 9,700 shares in the last quarter. FIL Ltd grew its holdings in shares of United Therapeutics by 0.7% in the third quarter. FIL Ltd now owns 467,147 shares of the biotechnology company’s stock valued at $59,739,000 after acquiring an additional 3,032 shares in the last quarter. Finally, Globeflex Capital L P bought a new position in shares of United Therapeutics in the third quarter valued at approximately $192,000. 93.69% of the stock is owned by institutional investors and hedge funds.

In related news, Director Christopher Causey sold 810 shares of the company’s stock in a transaction that occurred on Monday, September 10th. The stock was sold at an average price of $119.00, for a total value of $96,390.00. Following the transaction, the director now owns 1,555 shares in the company, valued at $185,045. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 8.20% of the stock is currently owned by corporate insiders.

United Therapeutics stock opened at $118.10 on Friday. United Therapeutics Co. has a 12 month low of $100.57 and a 12 month high of $152.55. The company has a current ratio of 4.32, a quick ratio of 4.05 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $5.11 billion, a P/E ratio of 10.84, a PEG ratio of 27.38 and a beta of 1.23.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, October 31st. The biotechnology company reported $2.42 EPS for the quarter, missing the consensus estimate of $3.23 by ($0.81). United Therapeutics had a net margin of 31.73% and a return on equity of 25.24%. The firm had revenue of $412.70 million during the quarter, compared to analysts’ expectations of $378.22 million. During the same quarter in the previous year, the company posted $4.69 EPS. United Therapeutics’s revenue for the quarter was down 7.4% on a year-over-year basis. On average, analysts predict that United Therapeutics Co. will post 14.28 earnings per share for the current year.

Several equities analysts have recently issued reports on the company. Credit Suisse Group reduced their target price on United Therapeutics from $106.00 to $103.00 and set an “underperform” rating for the company in a report on Thursday, November 1st. TheStreet raised United Therapeutics from a “c+” rating to a “b” rating in a report on Thursday, August 16th. BidaskClub lowered United Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, September 24th. JPMorgan Chase & Co. upped their target price on United Therapeutics from $118.00 to $126.00 and gave the company a “neutral” rating in a report on Friday, November 2nd. Finally, Wedbush set a $253.00 target price on United Therapeutics and gave the company a “buy” rating in a report on Wednesday, August 8th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. United Therapeutics has a consensus rating of “Hold” and a consensus target price of $134.00.

COPYRIGHT VIOLATION NOTICE: “United Therapeutics Co. (UTHR) Shares Sold by Schroder Investment Management Group” was first posted by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://www.com-unik.info/2018/12/01/united-therapeutics-co-uthr-shares-sold-by-schroder-investment-management-group.html.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

See Also: Outstanding Shares

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit